Cargando…
Low MxA Expression Predicts Better Immunotherapeutic Outcomes in Glioblastoma Patients Receiving Heat Shock Protein Peptide Complex 96 Vaccination
Heat shock protein peptide complex 96 (HSPPC-96) has been proven to be a safe and preliminarily effective therapeutic vaccine in treating newly diagnosed glioblastoma multiforme (GBM) (NCT02122822). However, the clinical outcomes were highly variable, rendering the discovery of outcome-predictive bi...
Autores principales: | Wang, Yi, Li, Chunzhao, Chi, Xiaohan, Huang, Xijian, Gao, Hua, Ji, Nan, Zhang, Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321638/ https://www.ncbi.nlm.nih.gov/pubmed/35903678 http://dx.doi.org/10.3389/fonc.2022.865779 |
Ejemplares similares
-
Resection of Noncontrast-Enhancing Regions Deteriorated the Immunotherapeutic Efficacy of HSPPC-96 Vaccination in Treating Glioblastoma
por: Chi, Xiaohan, et al.
Publicado: (2022) -
Immunotherapy with heat shock protein 96 to treat gliomas
por: Li, Chunzhao, et al.
Publicado: (2020) -
Detection of new biallelic polymorphisms in the human MxA gene
por: Duc, Tam Tran Thi, et al.
Publicado: (2012) -
Polymorphisms of the MxA and MxB genes are associated with biochemical indices and viral subtypes in Yunnan HCV patients
por: He, Mengzhu, et al.
Publicado: (2023) -
Conformational dynamics of dynamin-like MxA revealed by single-molecule FRET
por: Chen, Yang, et al.
Publicado: (2017)